NCT03773328View on ClinicalTrials.gov

A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2022

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2027

Conditions
Guillain-Barré Syndrome
Interventions
BIOLOGICAL

CK0801

CK0801 (Cord blood-derived T-regulatory cells)

Sponsors

Lead Sponsor

Cellenkos, Inc.
All Listed Sponsors
lead

Cellenkos, Inc.

INDUSTRY